

STUDY MATTERS

September 15, 2022

Wake NCORP Website: https://wakencorp.phs.wakehealth.edu/

Register Now!

Wake Forest NCORP Research Base Annual Meeting

October 10 – 11, 2022 @ The Marriott Grand Dunes Resort & Spa, Myrtle Beach, SC



Our keynote speaker this year will be Dr. Ray Osarogiagbon from the Baptist Memorial Health Care/Mid South Minority Underserved NCORP.

Please use the **Registration** link below to register for the upcoming 9th Annual Wake Forest NCORP Research Base Meeting, October 10 – 11, 2022 with the Northwest AHEC. You will be asked if you will attend In-Person or Virtual. The link below should take you to the facepage and a gray "Register" button. Once you click on this button, you will be asked to Sign In. If you do not have an account, you will need to create one at this time using the links on this page.

The group rate for **Hotel** reservations is no longer valid; however, rooms are still available- <u>https://www.marriott.com/en-us/hotels/myrgd-marriott-myrtle-beach-resort-and-spa-at-grande-dunes/overview/?scid=cd5470db-cd64-4033-afea-9c893567388c&gclid=Cj0KCQjwmouZBhDSARIsALYcourNBOS3YGxqXPowZyT8 g89VvOAKRSaRb48ld6FYlfgwZl6ykcKPobkaAh-EEALw_wcB&gclsrc=aw.ds</u>

To Be Rescheduled: October 12, 2022 iDAPT Training

Due to trainer conflicts, the iDAPT workshop that had previously been scheduled for October 12th immediately following the Wake Forest NCORP Research Base Annual Meeting will be rescheduled. We apologize for this inconvenience.

2022 Landscape Assessment

Data Requests

Investigators who wish to use the data for scholarly products should first seek approval from affiliated Research Base and then submit a request to the Landscape Committee using the following link: <u>https://redcap.wakehealth.edu/redcapccc/surveys/?s=P9FEAHJLFAWW44FW</u>

CCDR/Administrator leads at NCORP M/U and Community Sites will have access to affiliates/sub-affiliates dataset, if consent was provided. To request dataset or summary of results contact <u>NCORP@wakehealth.edu</u>

OPEN CALL FOR COMMITTEE MEMBERS

The Wake Forest NCORP Research Base is soliciting applications for NCORP Community/ M/U Community Site representatives for the Cancer Control and Cancer Care Delivery Research (CCDR) Scientific Committees and the Health Equity Core Committee.

Community site representation on all committees is being expanded. Responsibilities for members will include:

• Attend committee meetings (monthly for the scientific committees and quarterly for the Health Equity Core)

- Provide feedback about studies early and throughout the study lifecycle to improve feasibility and alignment of studies with community site priorities and provide feedback on implementation challenges
- Provide scientific/feasibility/equity review of new concepts/protocols
- Oversee active studies, including minority/underserved accrual progress
- Periodically review and make recommendations about committee priorities and activities
- Act as a liaison between NCORP community sites/investigators and the Wake Forest NCORP Research Base

We are looking for committee members who bring diversity with regards to their expertise, service within NCORP (PIs or scientific leaders, CRAs, research nursing, and Administrators), and background and populations engaged. Interested individuals should apply using the REDCap link below. The application will include a brief statement (5-10 sentences) on your prior involvement with the Wake Forest NCORP Research Base, experience with cancer control, cancer care delivery research, and/or health equity research, interest in committee service, and contributions to the diversity of the committee. You will also be asked to upload a CV or biosketch. The initial committee term will be 2 years. <u>The due date to apply is October 31, 2022.</u> Selection of committee members will take place in November and committees will begin meetings in January 2023.

Click here to

apply: https://redcap.wakehealth.edu/redcapccc/surveys/?s=PYEDAF7EFY78J773

For Funding Opportunities Announcements Relevant to NCORP CCDR, click on this link:

https://healthcaredelivery.cancer.gov/funding/opportunities.html

Upcoming Site Calls

If you would like to attend one of these calls, but did not receive an invitation, please email <u>NCORP@wakehealth.edu</u>

Click the button below the meeting to add it to your Outlook Calendar **Please note that your calendar may not update automatically if changes are made. Please check these emails and our website for meeting updates.**

You can also join site calls from our <u>Wake NCORP website</u>. Click the call in the "Upcoming Events" section on the Home page or through the Calendar.

WF1802- PCW- Influence of Primary Treatment for Prostate Cancer on Work Experience

September 20, 2022 at 1:30pm EDT. Please update your calendars.

Click here to add this WF1802-PCW meeting to your calendar

WF97415-UPBEAT - Understanding and Predicting Breast Cancer Events after Treatment

Meeting has been changed to "Bi-Monthly". The next site call will be September 21, 2022 at 1:00pm EDT. Please update your calendars.

Click to add this WF97415-UPBEAT meeting to your calendar

WF1805CD-HN-STAR - Implementation and Effectiveness Trial of HN-STAR

September 21, 2022 at 3:00pm EDT. Please update your calendars.

Click to add this WF1805CD-HN-STAR meeting to your calendar

<u>WF1801-RAMIPRIL - A Single Arm, Pilot Study of Ramipril for</u> <u>Preventing Radiation-Induced Cognitive Decline in Glioblastoma</u> (GBM) Patients Receiving Brain Radiotherapy October 5, 2022 at 2:00pm EDT. Please update your calendars.

Click to add this WF1801-RAMIPRIL meeting to your calendar

WF1806-M&M - Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer

October 12, 2022 Site Call is <u>cancelled</u>. Join us for the WF NCORP Research Base Annual Meeting on October 10-11th.

New Wake Forest NCORP Research Base Website


Please visit and register on our new Wake Forest NCORP Research Base website

https://wakencorp.phs.wakehealth.edu/

Registering for an account will allow you to:

- Join site calls and other meetings from the Upcoming Events or Calendar sections
- Access study training materials
- View previous study meetings
- Download important study documents including training videos, study guides, and neurocognitive CRFs

Once registered, you must update your user profile to sign up for study-specific mailing lists and meeting announcements, indicate your NCORP Community site, add your user roles, and update your GCP for database access.



Email Preferences

NCORP

Other

Subscribe to General Email Updates

General Studies

WF01213-RELAX

WF10217-WAYSWF1801-RAMIPRIL

☑ WF1802-PCW

WF1806-M&M
WF1901-IMPACTS
WF20817CD-OASIS
WF30917CD-TELEHEALTH
WF97115-ACUPUNCTURE
WF97116-REMEMBER
WF97415-UPBEAT
WF98213-PREVENT

☑ WF01414-NAVIGATOR

☑ WF1803CD-CAREGIVERS

VF1804CD-AH-HA

☑ WF1805CD-HN-STAR

- - Investigator

Roles

- NCORP Administrator
- CRA

CCDR Lead

- ☑ Data Management ☑ Regulatory
- Operations Manager
- 🗹 Quality Control

GCP certificate

Upload new certificate

Choose File No file chosen

Accepted file types: jpg, png, pdf, jpeg, Max. file size: 2 MB.



If you have any questions or need assistance with registration please email <u>NCORP@wakehealth.edu</u>

Please email <u>7NCORP@wakehealth.edu</u> when shipping biospecimen samples to the NCORP Research Base Biospecimens lab (Studies WF-97415, WF-1801, and WF-1901). Include the FEDEX tracking number in your email so that misplaced samples can be tracked before they spoil. Please ship by "FedEx Priority Overnight" (please change this on the pre-printed shipping label if this is not selected).

Study Updates

<u>WF-1801 - Ramipril - A Single Arm, Pilot Study of</u> <u>Ramipril for Preventing Radiation-Induced Cognitive</u> <u>Decline in Glioblastoma (GBM) Patients Receiving Brain</u> <u>Radiotherapy</u>

LabCorp Billing Errors

We are receiving monthly billing errors with the LabCorp lab orders. Please be very careful when picking your accounts when placing LabCorp orders. The WF-1801 account is only to be used for CMP's using your patient's PID. There are some sites who have incorrectly ordered tests using their patient's PHI for testing

that is not covered by WF-1801. Please relay this information to your colleagues who may be coordinating care for this study. Thank you.

WF-1802 - PCW - Influence of Primary Treatment for Prostate Cancer on Work Experience

The Higher Income AA stratum only has 1 remaining slot available. Please keep this in mind when screening for participants and check the slot reservation report in CTSU-OPEN to see how many slots are available before registering. Try to approach individuals from the lower income white strata that is slowly accruing. The lower income AA strata and higher income white strata are already closed.

WF-1805CD - HN-STAR - Implementation and Effectiveness Trial of HN-STAR

Data Entry Updates

- When entering Demographic Data in OPEN Step 1 for Survivors please pay close attention to Initials, Date of Birth, and Zip Code. Survivor Participants will be using these data points to log into the HN-STAR tool website and these must match the data in OPEN in order for the login to succeed.
- Several Survivors have reported not receiving emails sent through REDCap using our <u>NCORP@wakehealth.edu</u> email address. Please check with participants to make sure they are receiving these emails for Pre-Visit SSA, Post-Visit, Quarterly, and 1-Year surveys. If not, please verify email addresses and contact <u>NCORP@wakehealth.edu</u> so we can troubleshoot and make other arrangements. We only receive "bounce" messages for incorrect email addresses.

• For the best user experience, survey links should be opened in Google Chrome, Safari, or Firefox on a computer or tablet. Surveys are not optimized for smartphones and may not work.

WF-1806 - M&M- Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer

Spanish Consent Form Available

WF-1806 (M&M) Amendment 6, Protocol Version Date 06/24/2022, Release Date 08/03/2022

The Spanish version of the consent form which aligns with protocol version 06/24/2022 was posted to CTSU on **8/3/2022**. Re-consent is not required for your Spanish speaking participants. Spanish versions of the protocol supporting documents are unchanged and remain in force until an amendment is necessary.

- 1. CARE Questionnaire_v05.01.20_Spanish
- 2. Demographic and Health Behaviors_v05.01.20_Spanish
- 3. Hand-Grip Physical Test_v05.01.20_Spanish
- 4. Life-Space Survey_v05.01.20_Spanish
- 5. Short Physical Performance Battery Protocol_v05.01.20_Spanish
- 6. NCI PRO-CTCAE Items_v05.01.20_Spanish
- 7. GP5_v04.01.2021_Spanish

If there are any questions regarding the WF-1806 activation or site registration procedures, please contact <u>NCORP@wakehealth.edu</u>; Attn: WF-1806.

WF-1901 - IMPACTS - Internet-delivered Management of Pain Among Cancer Treatment Survivors

Recruitment Flyer with Opt-In Survey (version 07.29.22) Now Available Aligned with IMPACTS (WF-1901) Amendment 5, PVD 02/28/2022, Release

Date March 22, 2022

Two versions of a new recruitment flyer were posted to the CTSU website on 9/7/2022. You now have the option to use a site specific QR Code which links to a participant **opt-in survey** in REDCap. When using the QR code, site coordinators will be alerted when a potential participant fills out the survey. Site specific QR codes and printed flyers will be supplied by the Wake Forest Research Base IMPACTS Study Team.

		you	uro	an	cer	or	can	icer	tre	ea	tm	ent	?		
s c a t t	Pain* is one of symptoms in ca of the symptom adequately trea *Unpleasant sensor that may include elt painful discomfort s numbness, tingling	ancer ns lea: ated. y and e her phy uch as	patie st like motion /sical p aching	nts <u>a</u> ely to nai exp	nd or be	e		21	*	4	*	17		OP	
6	The IMPACTS S delivered Mana Among Cancer is designed to h pain so you car	ngerne Treat nelp y	ent of ment ou m	Pain Surv anag	i <i>vors,</i> e you	r	A SO			(A	- F	M
	life.														
i v c										ance	eror	cancer	treatme	ent are.	invited.
i v c t	life. Cancer patient:	ible p	artici	patio	n in t	he IN	IPACTS	study							
i ✓ (↓ ■ Base	life. Cancer patients to discuss poss	ible po for yo ipon: ays, hor	articij our tir se be w wou	patio me w low, ld you	n in t III be , you	provi may	ded. In	study n-pers igible	on a	ind i	remo e par	te visit t in th	s are ava	ailable!	tudy.
i ✓ (▼ (Base	life. Cancer patients to discuss poss Compensation ad on your res In the past seven d	ible po for yo ipon: ays, hor	articij our tir se be w wou	patio me w low, ld you	n in t III be , you	ne IN provi may pur pai	ded. In be el	study n-pers igible	on a to t a scal	ind i	e par om Q ti 9	te visit t in th	s are avi e IMPA 0 being N	ailable!	tudy.
i √ (Base 1. H	life. Cancer patients to discuss poss Compensation ad on your res In the past seven d	ible pi for yo ipon: ays, hor aginabl 0 No Pain is, how	articij our tir se be w wou le Pain 1	patio me w ilow, id you ? 2 did yo	n in t ill be you rate y	provi may our pai 4	ded. In be el	study n-pers igible rage on 5 7	on a to t a scal	ind i take le fre s	e par om Q ti 9	te visit t in th o 10 with 10 Worst Imagnabi Pain	s are avi e IMPA 0 being N	ailable!	tudy.
i √ (Base 1. H	life. Cancer patient: to discuss poss Compensation ad on your rei In the past seven d being the Worst Im In the past 3 month Never If you	for yc for yc pon: ays, hor aginabi 0 No Pain Sc Sc would	articij our tir se be w wou le Pain 1 often ome Da	patio me w Ilow, I	n in t ill be , you rate y 3 u have	provi may our pain: 4 pain: N o conto	IPACTS ded. In be el n on ave 5	study n-pers igible rage on 5 7 5 7 5 7	to t a scal	ind i take le fro	e par e par om Q,ti 9 Every	te visit t in th o 10 with Worst Imagnabi Pain Day	e IMPA 0 being N	ailable!	tudy.
i √ (Base 1. h	life. Cancer patient: to discuss poss Compensation ad on your rei In the past seven d being the Worst Im In the past 3 month Never If you	for yc for yc pon: ays, hor aginabi 0 No Pain Sc Sc would	articij our tir se be w wou le Pain 1 often ome Da	patio me w llow, lld you ? 2 did you 2 did you ys	n in t ill be , you rate y 3 u have	provi may our pain: 4 pain: N o conto	IPACTS ded. In be el n on ave 5	study n-pers igible rage on 5 7 5 7 5 7	to t a scal	ind i take le fro	e par e par om Q,ti 9 Every	te visit t in th o 10 with I0 Worst Imagnabl Pain Day	e IMPA 0 being N	ailable!	tudy.



Additional instructions may be found in the **2022.09.07** - **WF-1901 Site Recruitment Material Guide**, posted on the Wake Forest NCORP Research Base website IMPACTS Study Page on

9/7/2022; https://wakencorp.phs.wakehealth.edu/.

Resource for Usual Care Arm – Thank you note (version 07.29.22) Now Available

A "Thank you" note with instructions for accessing painTRAINER[®] has been approved by the CIRB and posted to CTSU on 9/7/2022. This should only be given to patients on the enhanced usual care arm who have **completed the study** and are interested in trying the internet program on their own.

antipal (desting providered provide
impacts
inquicis

Thank you for being a part of the IMPACTS study. Since you have completed all of the requirements on the usual care arm of our study, we would like to invite you to try the <u>painTRAINER</u>® tool on your own. Instructions are included below.

- painTRAINER' Start Up: You can use painTRAINER' on a smartphone, tablet computer, or personal computer. Supported web browsers include Chrome for Windows, Mac or Android phone/tablet. Edge for Windows or Mac. Safari for Mac.
- 2. Open your web browser and use it to go to the mypaintrainer.org website.
- Once you are on the mypaintrainer.org website, you will see the screen shown below. Now you need to register to use the program. Start by selecting REGISTER in the upper right corner of your screen.



 After you select REGISTER, you will see the screen shown below. Click in the white Study Code box to see a list of studies and select I'm not in a study. Create your own username, add your personal email and



Version 07/29/2022

WF-1901

If there are any questions regarding the materials listed above, please contact <u>NCORP@wakehealth.edu</u>; Attn: WF-1901.

WF-97116 - REMEMBER - A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairments

As we are updating our policies/procedures on CTSU study status, such as close

to enrollment, complete and FDAAA/IRB complete, we want to clarify the status for WF-97116 the Remember study.

We recently stated that your sites could close this study with your local IRB and/or CIRB, as it was assigned the status of *complete (Note Special Broadcast dated 08/01/22 and Study Matters dated 08/04/22)*. However, we ask that you <u>do not</u> <u>submit a request for closure</u> at this time, as the data is still being analyzed and audited during this *complete* status.

Going forward in our updated policies/procedures, we will not allow sites to close studies with their local IRB and/or CIRB until we have notified you that the study has been assigned the CTSU status of *FDAAA/IRB completed*.

If you have already closed this at your site with your local IRB and/or CIRB prior to today, we ask that you send us an email to <u>NCORP@wakehealth.edu</u> with your approved IRB closure memo to let us know.

We appreciate your cooperation and continued support to our studies!

<u>WF-97415 - UPBEAT - Understanding and Predicting Breast Cancer Events after</u> <u>Treatment</u>

Due to hardware issues there will be a delay in MRI image review report distribution. Please continue to submit MRI scans as usual. If there are any questions, please contact <u>NCORP@wakehealth.edu</u>. Attn: WF-97415.

UPCOMING PRESENTATIONS

UPBEAT WF97415	Longitudinal assessment of racial differences in exercise capacity after breast cancer treatment: WF-97415	Reding, KW, O'Connell, NS, Szewczyk, W, Cheng, RK, Nguyen, J, Ladd, A, Jordan, J, Lucas, A, Shepherd, V, Ge, Y, Salloum, F, Kim, Y, Lesnefsky, E, Franco, RL, Melendez, G, Sutton, A, D'Agostino Jr, R, Weaver, KE, Lesser, GJ, Hundley, WG	American Heart Association	Poster Session for in- person presentation	November 5– 7 2022	Chicago, IL
UPBEAT WF97415	Hypertension Severity Impacts Declines in Left Ventricular Ejection Fraction Among Women Receiving Adjuvant Chemotherapy for Breast Cancer (UPBEAT WF-97415)	Garg, R, O'Connell, N, Lesser, GJ, Jordan, JH, Sutton, A, Bottinor, W, Ladd, A, D'Agostino Jr., R, Hundley, WG, the UPBEAT Study Team	American Heart Association	Poster Session for in- person presentation	November 5– 7 2022	Chicago, IL

<u>WF-98213 - PREVENT - Preventing Anthracycline Cardiovascular Toxicity with</u> <u>Statins</u>

RECENT PUBLICATION

Hundley WG, D'Agostino R, Crotts T, et al. Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM Evidence. 2022:EVIDoa2200097.

Evidence

ORIGINAL ARTICLE

CURRENT ISSUE RECENTLY PUBLISHED AUTHOR CENTER ABOUT Q

:=
D
TOP
<
©

Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment

W. Gregory Hundley, M.D.¹, Ralph D'Agostino, Jr., Ph.D.², Teresa Crotts, B.S.³, Karen Craver, M.T.⁴, Mary Helen Hackney, M.D.⁵, Jennifer H. Jordan, Ph.D.^{1,6}, Bonnie Ky, M.D.⁷, Lynne I. Wagner, Ph.D.⁴, David M. Herrington, M.D., M.H.S.³, Joseph Yeboah, M.D.³, ... Show More ~

-	
	A CONTRACTOR OF A
	- Iweet
×.	- march

Published August 18, 2022 NEJM Evid 2022; 1 (9) DOI: https://doi.org/10.1056/EVIDoa2200097

ADVERTISEMENT

Issue >

Article	Figures/Media
---------	---------------

23 References 1 Citing Article

Abstract

BACKGROUND

Statins taken for cardiovascular indications by patients with breast cancer and lymphoma during doxorubicin treatment may attenuate left ventricular ejection fraction (LVEF) decline, but the effect of statins on LVEF among patients with no cardiovascular indications is unknown.

PREVENT WF98213	그 것을 잘 안 안을 가 안 했다. 그 집에는 것은 것을 가지 않는 것을 위한 것을 만들었다. 것을 것을 했는	Sutton, AL, O'Connell, NS, Lucas3, AR, Franco, RL, Reding, KW, Kim, Y, Cheng, R, Sheppard, VB, Weaver, KE, Lesser, GJ, Hundley, WG	American Heart Association	Moderated Digital Poster Session for in- person presentation	November 5– 7 2022	Chicago, IL	
--------------------	---	--	-------------------------------	--	-----------------------	-------------	--

Open Studies	Name	Enrolled (Patients)	Target (Patients)	Enrolled (Non- Patients)	Target (Non- Patients)
WF-1801	RAMIPRIL	57	75		
WF-1802	PCW	227	255		
WF-1806	M&M	100	300		
WF-1901	IMPACTS	60	456	0	40
WF-1804CD	AH-HA	488	600	24	40
WF-1805CD	HN STAR	101	350	73	140

Accruals as of September 14, 2022

Copyright © 2022 Wake Forest NCORP Research Base, All rights reserved.

Want to change how you receive these emails? You can <u>update your preferences</u> or <u>unsubscribe from this list</u>.

